2009
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research And Treatment 2009, 121: 301-309. PMID: 19603265, DOI: 10.1007/s10549-009-0445-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleFluorouracilGene Expression ProfilingHumansNeoplasm StagingOligonucleotide Array Sequence AnalysisPaclitaxelPredictive Value of TestsTreatment OutcomeConceptsBreast cancer cell linesCancer cell linesResponse predictorsBaseline gene expression dataCell linesChemotherapy drugsHuman breast cancer cell linesStandard chemotherapy drugsFine-needle aspiration specimensNeedle aspiration specimensPathologic responseAffymetrix U133A gene chipsClinical evaluationBreast cancerPharmacogenomic predictorsSame drugStage IPredictive valueAspiration specimensMultigene predictorsTumor samplesPatientsResistant cellsPatient dataDrugs
2006
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal Of Clinical Oncology 2006, 24: 4236-4244. PMID: 16896004, DOI: 10.1200/jco.2006.05.6861.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroarray AnalysisMiddle AgedNeoplasm StagingOligonucleotidesPaclitaxelPredictive Value of TestsReproducibility of ResultsROC CurveSensitivity and SpecificityPharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy
Esteva F, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar A, Hortobagyi G, Symmans W, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy. Journal Of Clinical Oncology 2006, 24: 545-545. DOI: 10.1200/jco.2006.24.18_suppl.545.Peer-Reviewed Original ResearchBreast cancerOverall pathologic complete response ratePathologic complete response rateTrastuzumab-resistant cell linesAbsence of trastuzumabOnly preoperative chemotherapyComplete response rateReceptor mRNA expressionFine-needle aspirationConcomitant trastuzumabFEC chemotherapyPreoperative trastuzumabQuantitative estrogenCyclophosphamide chemotherapyPreoperative chemotherapyNodal statusResidual diseaseTumor sizeClinical variablesNuclear gradeNeedle aspirationPharmacogenomic predictorsMolecular predictorsResponse rateTrastuzumab